PATINA Trial Summary: Adding Palbociclib to Maintenance Therapy in HR+/HER2+ Metastatic Breast Cancer

Background

The PATINA trial tested whether adding palbociclib to standard maintenance therapy improves outcomes in HR+/HER2+ metastatic breast cancer—a biologically distinct subtype where crosstalk between HER2, ER, and CDK4/6 pathways may drive resistance.

Study Design

This phase 3, open-label trial randomized 518 patients with HR+/HER2+ metastatic breast cancer who had not progressed after 4–8 cycles of trastuzumab-based induction (94% received dual HER2 blockade). Patients received maintenance anti-HER2 plus endocrine therapy with or without palbociclib.

Key Results

At median follow-up of 53.5 months:

– Median PFS: 44.3 vs. 29.1 months (HR 0.75; 95% CI 0.59–0.96; P=0.02)

– Confirmed response rate: 32.9% vs. 24.8%

– Clinical benefit rate: 88.9% vs. 80.9%

– Overall survival data immature (HR 0.86)

Safety

Toxicity was consistent with known palbociclib effects:

– Grade 3/4 AEs: 79.7%/10.0% vs. 30.6%/3.6%

– Grade 3 neutropenia: 55.9% vs. 2.0% (febrile neutropenia rare)

– Dose reductions: 58%; discontinuation for AEs: 18%

– No treatment-related deaths

Bottom Line

Adding palbociclib to maintenance anti-HER2/endocrine therapy extends median PFS by over 15 months in HR+/HER2+ metastatic breast cancer. Including induction, first-line disease control exceeded 4 years. Toxicity is manageable, primarily neutropenia. OS data are awaited.

Limitations: Open-label design, limited racial diversity, excludes patients progressing during induction.